Can Merck Beat Pfizer in This Multibillion-Dollar Vaccine Market?

·3 min read

Merck (NYSE: MRK) recently won U.S. Food and Drug Administration approval for its pneumococcal vaccine. Pfizer (NYSE: PFE) currently dominates the pneumococcal vaccine market, with its Prevenar 13 generating nearly $6 billion in sales last year. In this Motley Fool Live video recorded on July 21, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss whether or not Merck can beat Pfizer in this multibillion-dollar vaccine market.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting